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Introduction
▼
Ultrasound (US) has long been established as the
ideal first imaging examination in children, with
excellent diagnostic capabilities in the investiga-
tion of diverse body parts such as the abdomen,
the neonatal brain or the pleural cavity. Never-
theless, inherent limitations and the frequently
inconclusive nature of B-mode US may require
further cross-sectional imaging including Compu-
ted Tomography (CT) or Magnetic Resonance
(MR) imaging in order to increase diagnostic cer-
tainty. These investigations require contrast ad-
ministration, inevitably in CT and frequently in
MR imaging. Contrast agents in CT and MR ima-
ging are associated with increased risks both in
the adult and child, with gadolinium agents facing
greater scrutiny as to long term adverse effects,
pertinent to the child [1]. A further “hazard”
with the child entailed in CT and more often in
MR imaging is the need to render the child immo-
bile throughout the examination either with con-
scious sedation or general anaesthesia. However
the need to reduce radiation exposure in the child
is the over-riding aim of every imaging work-up
algorithm; cancer risk from medical exposure is
not a trivial issue [2–4]. Any adjuvant to the base-
line US investigation that can obviate the need for
further CT or MR imaging in the child would be
valuable.
Contrast-enhanced ultrasound (CEUS) with the
currently commercially available second genera-
tion US contrast agents (UCA) has become a stand-
ard imaging option in adult clinical practice for a
number of years with an exceptionally high safety
profile [5]. Adult CEUS practice across many body
organs is established with detailed guidelines on
the application published [6, 7]. Many of the appli-
cations are “off-label” but the justification for this
is often supported by clinical evidence of the use-
fulness of CEUS [8, 9]. The extension of CEUS into
paediatric clinical practice has been slow to devel-
op, mainly hampered by the lack of a “licence” and
clinical experience; neither an unsurmountable
issue. The use of “off-label” drugs in paediatric
practice is well known [10–12] and the justifica-
tion for “off-label” use is sanctioned by themedical
regulatory authorities [13]. Previously the only li-
cence for the use of CEUS in paediatric practice
was for vesico-ureteric reflux using an agent not
currently marketed [14]. There is increasing evi-
dence for the safe intravenous use of UCA in chil-
dren [15–17]. Diagnostically efficient investiga-
tions using intravenous CEUS in children are
increasingly reported [18–21].
Among the currently available second generation
UCA, two have been already used in children; So-
noVue™ (Bracco SpA, Milan) containing sulphur
hexafluoride gas microbubbles and Optison™
(GE Healthcare Inc., Princeton, NJ) containing per-
flutren gas microbubbles. Recently the Food and
Drug Administration (FDA) in the United States of
America has authorized the use of SonoVue™ un-
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Abstract
▼
The use of contrast-enhanced ultrasound (CEUS) in
adults is well established in many different areas,
with a number of current applications deemed
“off-label”, but the use supported by clinical ex-
perience and evidence. Paediatric CEUS is also an
“off-label” application until recently with approval
specifically for assessment of focal liver lesions.
Nevertheless there is mounting evidence of the
usefulness of CEUS in children in many areas, pri-
marily as an imaging technique that reduces expo-
sure to radiation, iodinated contrast medium and
the “patient-friendly” circumstances of ultrasono-
graphy. This position statement of the European
Federation of Societies in Ultrasound andMedicine
(EFSUMB) assesses the current status of CEUS ap-
plications in children and makes suggestions for
further development of this technique.
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der the commercial name Lumason™ for liver applications in
paediatric patients, which is likely to have a profound effect on
paediatric US imaging worldwide [22, 23]. This position state-
ment of the European Federation of Societies in Ultrasound and
Medicine (EFSUMB) assesses the current status of CEUS applica-
tions in children and makes suggestions for further development
of this technique.
General Considerations
▼
The issue of consent for the CEUS examination is complex. In
most cases the administration of the UCA is “off-label”, and writ-
ten consent for UCA administration may be a hospital require-
ment. The consent should be obtained fromparents or legal guar-
dians prior to examination. However, local policies may vary and
informed verbal consent is all that may be required. Some hospi-
tal authorities require written consent for all contrast examina-
tions, and administration of an UCA should also be included in
this requirement.
The standard manufacturer’s list of contraindications needs to be
observed. Contraindications include a history of known hypersen-
sitivity to the active substance or excipients, childrenwith right-to-
left shunts, severe pulmonary hypertension, uncontrolled systemic
hypertension, and uncertain pregnancy status where applicable.
As with all contrast administration, ready access to resuscitation
equipment is mandatory and should be in close proximity to the
roomwhere CEUS examinations are conducted. All personnel in-
volved with UCA administration in children should have basic
skills in identifying and treating a contrast reaction in a child.
Paediatric CEUS Safety Considerations
▼
Safety regarding the intra-venous use of UCA in the children is
principally focused on the “off-label” usage. Despite the variabil-
ity in the legislation between different countries, the “off-label”
use of pharmaceutical products in children is a relatively com-
mon phenomenon; 11–37% of outpatient treated children, 16–
62% of in-patient treated children and 51–80% of neonatal pa-
tients may have received “off-label” medications [10–12]. The
“off-label” use of a pharmaceutical product may be considered
appropriate in cases where the benefits of its use outweigh the
potential risks of non-treatment. In this context, paediatric CEUS
has the potential to influence or even change the diagnostic and
therapeutic decisions.
The safety profile of UCA during intravenous administration has
been documented in a large cohort of 23188 adultswith the second
generation UCA SonoVue/Lumason™ (Bracco SpA, Milan), with no
fatal event encountered and only 29 (3 severe, 3 moderate and 23
mild) adverse reactions noted [5]. The overall rate of adverse events
(0.0086%) was comparable to the administration of contrast media
used inMR imaging (0.0088%) [24] and considerably lower than io-
dinated contrast media used in CT imaging (0.6%) [25].
The safety profile of UCA in children is based on limited informa-
tion; there are only three dedicated safety studies which have in-
cluded vital signs monitoring, all using perflutren containing
UCA [17, 20, 26]. In a study of 13 children who underwent intra-
venous CEUSwith escalating doses of UCA based on the body sur-
face, three children experienced mild adverse events; two had
altered taste and one mild tinnitus and light-headedness [20]. In
a further study by the same group, 134 CEUS examinations in
34 children (median age 8.7 years) were evaluated, reporting a
similar frequency and nature of adverse reactions [17]. In a study
of 20 children (median age 15 years) four experienced adverse
reactions, three children developed transient headache and one
reported brief alteration of taste sensation [26].
A sulphur hexafluoride gas containing UCAwas also evaluated in
a dedicated safety evaluation study of 161 intravenous CEUS in-
vestigations in 137 children (median 10.2 years) [21]. In a single
case (0.6 %), severe anaphylactoid shock, potentially life threaten-
ing and directly related to the intravenous UCA administration
was encountered. Observed symptoms were generalized pruri-
tus, nausea, and hypotension with tachycardia initially then bra-
dycardia. Management consisted of oxygen, intravenous epine-
phrine and fluids (0.9% normal saline) with resolution in two
hours. In 37 children who underwent intravenous CEUS, an 8-
year-old girl reported nausea 15 minutes after UCA administra-
tion, which continued for 30 minutes [27]. In addition, a retro-
spective survey analysis of 948 examinations (29 European
centres) all performed with SonoVue™/Lumason™, five minor
adverse events were recorded; skin reaction, unusual taste and
hyperventilation were observed [28].
More extensive safety data has been recorded with intra-vesical
administration of UCA during contrast-enhanced voiding urosono-
graphy (ceVUS) in a total of 13 studies encompassing 2087 chil-
dren [29–42]. In the majority of these studies safety data was ac-
quired from the time of the examination and up to 48 hours
following the examination. No serious adverse events were en-
countered, with only 3.7% of children reporting minor adverse
events in one safety-dedicated study, which included symptoms
of dysuria, abdominal pain, blood and mucous discharge, perineal
irritation and urinary tract infection [35]. Symptoms such as anxi-
ety and crying over micturition were also encountered and were
likely attributed to the procedural technique rather than the UCA
administration, as similar events are reported with other imaging
examinations entailing bladder catheterization. Furthermore, In-
cluded in the retrospective survey analysis among 29 European
centres, 4131 children underwent ceVUS with only minor dysuria
symptoms reported [28].
No study has evaluated the in-vivo interaction between UCA and
bladder urothelium. A few experimental studies have shown that
in the presence of gas-filled microbubbles, the interaction of tis-
sues and US waves may result in decrease of tissue cavitation
threshold and possible disruption of cellular membranes result-
ing in haemolytic events. However, this phenomenon, which is
frequency dependent, has been described in-vitro, with US fre-
quencies that are above the diagnostic medical range [43].
Position Comment
The evidence to date suggests than the safety profile of UCA in
adults is good, and comparable to contrast agents used in MR ima-
ging, better than the contrast agents in CT imaging. The more lim-
ited safety data in children suggests that UCA are as safe in children
as in the adult population.
Current Applications
▼
Focal Liver Lesions
Background
The evaluation of focal liver lesions (FLL) that are detected during
baseline US in underlying normal or diseased livers is an important
application for CEUS in children. Similarly to that established in
Sidhu PS et al. Role of Contrast-Enhanced… Ultraschall in Med
Guidelines & Recommendations
T
h
is
 d
o
c
u
m
e
n
t 
w
a
s
 d
o
w
n
lo
a
d
e
d
 f
o
r 
p
e
rs
o
n
a
l 
u
s
e
 o
n
ly
. 
U
n
a
u
th
o
ri
z
e
d
 d
is
tr
ib
u
ti
o
n
 i
s
 s
tr
ic
tl
y
 p
ro
h
ib
it
e
d
.
adults, there is the potential in paediatric diagnostic practice for
CEUS to have a higher diagnostic accuracy in the evaluation of a
FLL compared to grey scale US supplemented by colour Doppler
techniques and perhaps with comparable accuracy to contrast-en-
hanced CT and MR imaging. This could potentially include Focal
Nodular Hyperplasia (FNH) with typical and diagnostic appearan-
ces on CEUS but non-specific B-mode US features, obviating the
need for further cross-sectional imaging. Other commonly report-
ed benign FLL that could be accurately characterized by CEUS in
children are haemangiomas, hepatocellular adenomas, hepatic
cysts, abscesses, regenerative nodules and focal areas of fatty spar-
ring or infiltration. Furthermore, CEUS can provide information in
identifying viable tissue within a FLL, allowing a targeted biopsy
and facilitating accurate tissue sampling. Contrast-enhanced ultra-
sound can reveal the presence of additional lesions, not detected
during preceding B-mode US.
Technical Aspects
Following intravenous administration of a single UCA dose, tar-
geted evaluation of enhancement dynamics is performed under
real-time US imaging in all vascular phases. The enhancement
patterns of the FLL are similar to the well-described enhance-
ment patterns noted in CT and MR imaging, with the hallmark
of contrast “hypo-enhancement” during the portal venous phase
being indicative of malignancy [6]. There are no standardized
dosage schemes of the administrated UCA for paediatric CEUS. In
published studies of paediatric liver CEUSwith SonoVue™/Luma-
son™, the volume of a single SonoVue™/Lumason™ dose ranges
between 0.1mL to 4.8mL. The volume of the administered UCA is
extrapolated from the licensed adult dose for liver applications
and has been described to be adjusted according to child’s age,
body surface or body weight in the case of obese children as well
as the type of US scanner, transducer and processing software
used e. g. (a) 0.1mL of SonoVue™/Lumason™ for each year of
age [27] and (b) standard single dose of 0.1mL, 0.5mL, 1mL,
1.2mL, 2.4mL or 4.8mL of SonoVue™/Lumason™ [44–47]. The
recommendation of the FDA for the dose of SonoVue™/Luma-
son™ in children is based on bodyweight; 0.03mL/kg as an intra-
venous injection, up to a maximum of 2.4mL per injection [23].
Overall, it is accepted that the dose of the administrated UCA
may be reduced in children. Moreover, the timing of the liver vas-
cular phases is different in children compared to adults and sig-
nificantly varies depending on the child’s age [48]. It should be
noted that arterial phase imaging of liver in infants might begin
approximately 5–6 seconds following intravenous administra-
tion of microbubbles and the site (peripheral or central) of intra-
venous access has further influence [49].
Level of Evidence
There is accumulating evidence regarding the intravenous appli-
cations of UCA for the characterization of FLL in children. This ex-
perience stems from limited cohort studies and case reports en-
compassing exclusively paediatric patients as well as from larger
studies entailing mixed adult and paediatric patients.
In total 4 original paediatric studies including 125 children (new-
born to 18 years old) have been conducted for evaluation of FLL
[21, 27, 45, 46]. The largest series of FLL evaluated with CEUS to
date described 44 children (median age 11.5 years) evaluated for
the characterization of FLL detected during B-mode US imaging
[45]. In all cases CT imaging was used as a reference examination
and in some cases MR/ PET CT/histology results were also avail-
able. This study included primarily benign FLL and demonstrated
98% specificity of CEUS in accurately confirming the benign na-
ture of FLL based on the enhancement patterns and the absence
of contrast “wash-out” during portal venous phase. Importantly,
many original studies, including mixed adult and paediatric pa-
tients, have been conducted for evaluation of FLL [50–59]. All
studies demonstrated the feasibility, safety and high diagnostic
accuracy of CEUS regarding the characterization of FLL, similar
to CT and MR imaging. In the European survey of paediatric
CEUS, of the 948 pediatric CEUS examinations performed with
intravenous UCA [28], evaluation of FLL was the most common
indication. A recent review of the literature on paediatric intrave-
nous applications of CEUS in 2015 described 540 published pae-
diatric CEUS examinations with liver examinations the most fre-
quent indication, 41% of these cases [16].
A further six review articles that emphasize the advantages of
paediatric intravenous CEUS for the evaluation of FLL and pro-
mote the need for incorporation of CEUS into routine clinical
practice have been published [15, 45, 60–64]
Position Comment
Characterization of FLL in children is among the most commonly
reported application of paediatric intravenous CEUS. The en-
hancement patterns of FLL in CEUS are similar to other imaging
modalities and contrast “hypo-enhancement” during portal ve-
nous phase is highly specific for malignancy.
Renal
Background
The clinical impact of CEUS in renal disease is less well-documen-
ted than in the liver, and its ultimate role is still subject to debate,
with a recent review documenting current adult practice [65].
The most frequent paediatric CEUS application of the urinary
tract is ceVUS, with the intra-vesical UCA administration for the
assessment of vesical-ureteric reflux (VUR). The EFSUMB guide-
lines have established adult indications of renal intravenous
CEUS [7] with little published data available regarding paediatric
indications [66, 67]. Potential uses of intravenous CEUS in chil-
dren include diagnosis and follow-up of complicated infection
(abscess), cystic masses and complicated cysts, renal trauma, in-
farction, cortical necrosis [68], transplants, tumour vascularity,
renal artery stenosis and where there is a contraindication to CT
or MR imaging contrast agents.
Technique
With a single vascular supply to the kidney, compared to the dual
supply of the liver, a smaller dose of the UCA is needed for renal
opacification. After a very short period of cortical enhancement
(5–10 seconds after IV bolus injection), UCA can be seen the
medullawhich lasts 45–120 seconds after injection. The contrast
enhancement of the cortex occurs almost immediately after the
arrival of the UCA in themain renal artery, with rapid subsequent
renal vein enhancement [65, 69]. Limitations of renal CEUS are
identical to all US abdominal studies in children; lack of respira-
tory cooperation can limit the observation during the short corti-
cal phase and the simultaneous comparison with contralateral
kidney is not possible. Furthermore, as the contrast agents are
not excreted by the kidney, function and evaluation of the pelvi-
calyceal system is not possible.
Level of Evidence
Diagnosis of abscesses complicating pyelonephritis and response
to antibiotic treatment can be documented by CEUS (a central de-
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fect with rim enhancement). Complicated renal cysts are infre-
quent in children but CEUSmay be appropriate for renal cyst clas-
sification with the modified US Bosniak system [65], and the true
nature of indeterminate masses in children may be helped using
CEUS.A particular advantage of a CEUS examination is the better
depiction of internal vascularity of a lesion compared toMR or CT
imaging, potentially evaluating solid renal tumor vascularity
prior to and during chemotherapy [67]. CEUS can be used to de-
termine the extent of renal parenchymal injury in blunt abdomi-
nal trauma, and useful in the followup of parenchymal injuries or
for the assessment of complications after the admission CT ima-
ging [70, 71]. Acute renal transplant rejection may potentially be
diagnosed by CEUS, as well as stenosis and occlusion of the trans-
plant renal artery in the early stages [72].
Position Comment
Renal assessment in blunt abdominal trauma is promising with
evidence to indicate usefulness in follow-up. There is no data
available on the assessment of focal lesions, cysts and in the as-
sessment of renal transplants in the child; indications are likely
to be similar to those in the adult with more emphasis on child-
hood renal lesions with attention to tumour vascularity.
Abdominal Trauma
Background
The use of paediatric CEUS in the clinical setting of blunt abdom-
inal trauma is attractive. Other techniques that assess blunt ab-
dominal trauma in children such as Focused Assessment with So-
nography for Trauma (FAST) and CT imaging both have inherent
constraints. A FAST examination is sensitive in detecting free
peritoneal fluid as an indirect sign of injury but has poor sensitiv-
ity in directly revealing solid organ injury. Contrast-enhanced CT
is over utilized in trauma patients, imaging unnecessarily a wide
spectrum of severity, ranging from minor, single-system injuries
to devastating, multi-trauma; a balance needs to be achieved in
the child. As in adults, paediatric CEUS is an effective alternative
or supplementary imaging option to CT imaging in the following
situations: (a) in haemodynamically stable patients who sus-
tained isolated, low or moderate energy blunt abdominal trau-
ma; (b) in patients with indeterminate or normal CT findings
and suspicious laboratory tests; (c) in the follow-up of traumatic
injuries that are managed conservatively in order to ensure reso-
lution of the lesions or detect any associated complications, in-
cluding pseudoaneurysm formation [19, 71, 73–75]. CEUS can
identify traumatic injuries and evaluate their extension with
higher diagnostic accuracy compared to baseline US and compar-
able to CT imaging, and can detect associated complications [76].
Technique
CEUS in trauma is performed following bolus intravenous admin-
istration of two separate UCA doses. The first dose is adminis-
tered to investigate organs in the right upper quadrant (kidney,
adrenal gland, pancreas and liver), whereas the second is admi-
nistered to evaluate organs in the left (kidney, adrenal gland and
spleen). The CEUS examination should commence from the side
of clinical concern. The kidney should be examined first as this
will rapidly enhance, with a detailed examination throughout ar-
terial phase, whereas the spleen, and liver are evaluated during
the portal venous phases. Any traumatic lesion, laceration or con-
tusion, will appear as a clearly demarcated hypoechoic area com-
pared to the adjacent parenchyma. Follow-up CEUS imaging tar-
gets only the organ identified on baseline imaging, and a single
dose of UCAwill suffice.
Level of Evidence
There are a number of studies relating specifically to the assess-
ment of blunt abdominal trauma in children [19, 68, 71, 73, 75,
77]. The largest series of children (n=74) underwent comparative
B-mode US, CEUS and CT [19]. The diagnostic performance of CEUS
was better than B-mode US and similar to CT imaging. Moreover,
CEUS identified prognostic factors for the clinical course of trauma
patients, such as parenchymal active bleeding (n=8) and partial
splenic devascularization (n=1). A previous study with a smaller
number of children (n=27), demonstrated a sensitivity and speci-
ficity for CEUS compared to CT for the detection of solid organ in-
juries at 92.2% and 100% respectively [73]. A study that evaluated
the incidence of post-traumatic complications in a cohort of 17
children, demonstrating 83% sensitivity and 92% specificity of
CEUS for the accurate detection of liver and splenic pseudoaneur-
ysms [71]. A number of case reports present CEUS imaging findings
in isolated pancreatic and splenic injuries, as well as a case of renal
cortical necrosis [68, 71, 75]. A number of studies including a mix-
ture of adult and paediatric patients are described in the literature,
all large cohorts, demonstrating the feasibility and the high diag-
nostic accuracy of CEUS in the diagnostic algorithm of solid organ
injuries [19, 73, 74, 76–84].
Position Comment
CEUS has shown to be a reliable tool in the diagnosis and follow-
up of solid organs injuries in paediatric patients who sustained
low to moderate energy traumatic events, with the important
advantage of being a highly sensitive, radiation free and child
friendly imaging technique, allowing for repeated imaging. This
should form the basis of follow-up of solid organ injury to reduce
radiation and the use of iodinated contrast agents.
Pediatric Transplantation
Background
Possible indications for the application of CEUS in children with
transplantations (renal, liver, pancreas and renal combined), are
likely similar to adult indications, and the application of CEUS to
the imaging assessment is likely to be of substantial clinical rele-
vance. Most adult investigations have focused on the liver [51,
85–88] pancreas [89]and kidney [90–95]. Assessment of a num-
ber of potential areas in the transplanted child include differen-
tiation of incidental focal liver lesions [96], suspected post-trans-
plant-lymphoproliferative disease (PTLD), paediatric tumour
characterization before and after transplantation, depiction of
vascularity, vascular patency before and after solid organ trans-
plantation (liver [97], kidney, pancreas, bowel) or skin flaps [98],
ischemic alterations such as infarction, active bleeding, graft vs.
host disease (GVHD) [99] of the bowel and infectious complica-
tions after transplantation.
Level of Evidence
Nearly all studies of the use of CEUS in transplantation combine
adult and paediatric patients. The identification of complications
following solid organ or stem cell transplantation using CEUS can
confirm the preliminary clinical diagnosis, provide additional in-
formation relevant to the therapeutic management and obviate
any additional diagnostic procedure.
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Position Comment
The application of CEUS in the child following transplantation is
likely to be similar to the adult, with vascular patency, areas of
necrosis, assessment of new focal lesions and the assessment of
post-operative complications (e. g. fluid collections) most likely
the areas of use.
Lung and Pleural Space
Background
Although US has been applied for the evaluation of consolidated
lung and the adjacent pleural spaces in adults, the use of CEUS in
children has not been comprehensively described. However, there
are reports that suggest that CEUS may improve the diagnostic
confidence of grey scale US supplemented by colour and power
Doppler imaging in differentiating consolidated lung from cavitat-
ing pneumonia in children, and better delineating the extend and
contents of associated para-pneumonic fluid collections [100–
107]. In addition, there is limited evidence that CEUS can evaluate
the enhancement dynamics in cases of pleural-based lesions, al-
lowing for their improved characterization [101, 106].
Technique
Following UCA administration, targeted evaluation of the lung and
pleural spaces is performed in coronal plane using lateral and pos-
terior acoustic windows, in a comparable manner to grey scale
lung US. There are no standardized dosage schemes for this appli-
cation in the pediatric population; however a single dose of 2.4mL
has been described [100].
Level of Evidence
There is one study presenting the CEUS patterns in cases of pneu-
monia in a population group consisted of 50 adults and children
older than 17 years. In this study, evaluation of the affected lung
in terms of blood supply and enhancement could be used as
prognostic indicator for development of associated complications
[100]. Investigation by CEUS of lung and pleural lesions in chil-
dren are also described [101, 104].
Position Comment
Lung CEUS is a relatively new diagnostic method that could po-
tentially increase the diagnostic confidence to differentiate con-
solidated lung from cavitating pneumonia in children. This tech-
nique may also improve the visualization of pleural fluid.
Spleen
Background
Trauma is an indication for use of CEUS of the commonly injured
spleen in children, with CEUS of significantly higher sensitivity for
the diagnosis of splenic laceration, rupture, fracture or active
bleeding than B-mode or Doppler US [19, 71, 74, 75, 108]. This
has the potential to reduce the radiation exposure [109] with fol-
low-up imaging performed with targeted CEUS of the spleen once
baseline imaging (either CT or US as the situation decrees) con-
firms the site and extent of injury [7, 71]. Splenic diffuse or focal
pathology is difficult to characterize and differentiate on any ima-
ging modality. Suitable indications in children are the differential
diagnoses of splenic focal lesions (e. g. lymphoma, haemangioma
[110], complex cyst and abscess) and vascular alterations such as
splenic infarction, aneurysms and quantification of viable par-
enchyma in hyposplenia in sickle-cell disease [67]. In children, the
percentage of inborn focal splenic lesions such as hamartoma or
lymphangioma and the range of differential diagnoses due to me-
tabolic diseases might be higher compared to adults.
Technique
The intravenous administration of US contrast will mirror the
doses in adults; usually a smaller dose (typically 1.2mLs Sono-
Vue™/Lumason™ in adults) will suffice in the child. Careful con-
sideration of the unique vascularization pattern of the spleen to
avoid misinterpretation of abnormalities must be observed [7].
Typically, evaluation of the splenic parenchyma is performed
during venous and delayed phases.
Level of Evidence
Evidence for splenic pathology, apart from trauma, is sparse. There
is strong evidence for the application of CEUS in splenic trauma.
Position Comment
Diagnosis and follow-up of splenic trauma in children is an ideal
application of CEUS.
Adrenals
The value of conventional US in the detection of adrenal gland tu-
mours is well known; lesions >10mm are detectable, but charac-
terisation is more difficult. The differentiation of benign and ma-
lignant adrenal gland tumours is not possible using CEUS [111–
113]. No data regarding the use of CEUS in children for further
characterization of adrenal gland tumours is available. Isolated
case reports documenting adrenal lesions in children are avail-
able [114, 115]. Evaluation of trauma to the adrenal gland and
differentiation of haematoma from underling adrenal gland tu-
mour may be helpful [77]. Future perspectives of CEUS include
evaluation of haemorrhage in neonates.
Position Comment
Adrenal CEUS could be used in trauma or haematoma of the adre-
nal, evaluating resolution in place of CT.
Inflammatory bowel disease
Background
The diagnosis of inflammatory bowel disease (IBD) in children
and the classification of Crohn's disease (CD) or ulcerative colitis
(UC) is achieved with the combination of endoscopy, biopsy, la-
boratory markers and imaging work-up. Though CT Enterogra-
phy (CTE) and MR Enterography (MRE) are the diagnostic exam-
inations of choice for IBD in children, the role of CEUS is
increasing. Similarly to adults, paediatric CEUS has proved to de-
termine accurately the extent of the disease, differentiate be-
tween actively inflamed bowel and chronic fibrotic strictures,
evaluate the response to treatment, and identify the presence of
associated mural and extramural pathology. In addition, post-
processing quantitative evaluation of the visualized bowel wall
enhancement through assessment of time-intensity curves al-
lows for objective and reproducible evaluation of the degree of
bowel wall enhancement.
Technique
A fasting period of 6 hours is required. Initially, an unenhanced
US examination is performed supplemented by colour and power
Doppler US to identify the pathologically thickened loop of small
bowel. Following intravenous UCA administration, the involved
intestinal segment is targeted for CEUS evaluation of the degree
of bowel wall enhancement. There is no standardized dosage
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scheme for CEUS performance in IBD. The most commonly used
schemes are associated with the frequency of the used transduc-
er and are the following: (a) 1.2mL SonoVue™/Lumason™ in the
case of low-frequency transducers [116, 117], and (b) 2.4–4.8mL
in the case of high-frequency transducers [116]. The first-pass of
the small bowel enhancement is generally monitored 5 sec after
UCA injection and the maximum enhancement of the bowel wall
is visualized after approximately 12–20 sec. Serial static images
and multi-frame cine-clips during breath-holding are acquired
and are available for post processing quantitative analysis, which
includes evaluation of the following parameters in an operator-
defined Region of Interest (ROI): percentage of maximal en-
hancement, time to peak, and area under the curve. These
parameters were shown to have good correlationwith endoscopy
and histology grading.
Level of Evidence
There are no dedicated CEUS studies for the evaluation of IBD in
children. Among several published studies, five included mixed
population comprised of children older than 16 years of age and
adults [116–120]. All of these studies demonstrated the effec-
tiveness of CEUS in evaluation of IBD inflammatory activity and
a strong correlation with the histological indices. A single case
study regarding CEUS in epiploic appendagitis in child differen-
tiation of phlegmonous infiltration from abscess formation ap-
pears to be a useful indication [121].
Position Comment
CEUS can be used as an alternative imaging modality for the fol-
low up of children with known IBD to differentiate between ac-
tive and quiescent disease and to evaluate the outcome of thera-
peutic strategies.
Intra-cavity
Background
Intra-cavitary and extravascular administration of UCA is an ex-
panding off-label application, with numerous reported cases, but
no prospective studies documented [7]. Although no specific re-
commendations have been issued, its use has been advocated
where conventional techniques have either failed to reach a diag-
nosis or, importantly, are deemed to carry a higher risk (e. g. ionis-
ing radiation on sensitive organs). This is of particular importance
in children, where efforts to find alternative imaging solutions to
techniques involving ionizing radiation are paramount.
Technique
No standard doses are recommended with the reported range
from 0.1mL to 1mL of SonoVue™/Lumason™ diluted in 0.9 %
normal saline, depending on the type of cavity (physiological or
not) and the aim of the study. To demonstrate a possible commu-
nication or fistulous track between two cavities a higher dose of
1mL or 2mL will be needed, whereas to delineate a pathological
cavity (e. g. abscess), only a few drops are recommended to avoid
artefacts and obscuration of the far field [122].
Level of Evidence
There is currently no literature focusing on intra-cavitary use of
CEUS in children. A few applications of intra-cavitary CEUS in
adults that can be applied to paediatric patients have been de-
scribed. Trans-catheter use to evaluate the anatomy of the biliary
tract and to detect obstruction or biliary leakage following T-tube
removal has diagnostic accuracy comparable to percutaneous
trans-hepatic cholangiography [122–126]. Trans-catheter CEUS
in non-physiological cavities can allow identification of complica-
tions related to insertion of drainage tubes (such as dislocation or
obstruction), and also give a quantitative measure of the volume of
fluid present in a collection [127]. This technique may be uniquely
useful in the nephrostomy tube or pleural space empyema where
the visualization of the inter-costal drainage tube may be difficult.
In the latter, trans-catheter CEUS could rapidly resolve this issue,
even in a non-cooperating child, and direct management with fi-
brinolysis. Likewise, the injection of dilute UCA may guide ade-
quate positioning of the tip of the catheter when managing a mul-
ti-loculated intra-abdominal or pelvic abscess.
Position Comment
The potential use of trans-catheter injection of UCA has been
demonstrated in adults with possible uses in the child needing
exploration, with the most likely use in the assessment of the
pleural space in the presence of an empyema.
Vascular applications: Neurosurgical and tumour
response to antiangiogenic therapy
Background
Although the use of CEUS has been established in the vascular
field for carotid, abdominal aorta and cerebral vessels in the adult
population, there is a limited role in children. One area that vas-
cular application may be useful is in an intraoperative setting in
neurosurgical intervention for the evaluation of brain lesions
[128–130]. There is increasing evidence that CEUS can allow for
evaluation of the enhancement pattern of the tumour compared
to the adjacent normal parenchyma, improved delineation of the
tumor borders, visualization of the afferent, efferent or intra-le-
sional vessels, differentiation between viable tissue and areas of
cystic degeneration or tumor necrosis and potentially identifica-
tion of residual tumor. Quantification methods looking at the
vascularity of a tumour, based on the time-intensity curves is
useful to monitor response to antiangiogenic therapy in malig-
nancy [131] and this has been applied to tumour response in
children [132].
Technique
Initially, the lesion is visualized during B-mode US imaging, along
with the healthy brain tissue. The US transducer is positioned
over the lesion and after a bolus UCA injection, a digital cine clip
of the lesion is recorded for up to 2–5min to allow for offsite eva-
luations. The most commonly reported SonoVue™/Lumason™
dose is 2.4mL [128–130]. Qualitative analysis is performed for
comparison of the enhancement pattern of the tumour compared
to the adjacent normal brain tissue. In the tumour response pa-
tients, a bolus techniquewith the transducer placed over a region
of interest, with subsequent evaluation of various aspects of the
wash-in and wash-out curves [132].
Level of Evidence
Mixed case series of adult patients have described a few paedia-
tric cases using intraoperative CEUS in diagnostics of brain le-
sions. This includes an 11-year-old patient in whom intraopera-
tive CEUSwas effective to precisely localize the brain tumour and
search for tumour tissue residual after the initial resection [129],
and the usefulness of intraoperative CEUS examination was eval-
uated in a 13-year-old patient with arteriovenous malformations
to discriminate between the afferent and efferent vessels of the
lesion [130]. A cohort of 17 patients assessed for tumour vascu-
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larity, targeting lesions in various locations, including liver and
pleura, successfully predicted time to progression in a cohort of
children and adolescents with recurrent solid tumours treated
with antiangiogenic therapy [132].
Position Comment
CEUS is a promising imaging tool that may yield significant im-
provement in the macro- andmicro-vascular assessment in tran-
scranial ultrasound imaging. Tumour response following chemo-
therapy using the vascular enhancement may be better suited to
follow-up in children.
Vesico-ureteral reflux (VUR)
Background
Contrast-enhanced voiding urosonography is a well-established
application of paediatric CEUS. The examination entails bladder
catheterization and intravesical UCA administration under real
time US imaging. The main indications are the detection and
grading of VUR and urethral imaging in children. There are nu-
merous studies comparing ceVUS with the ionizing radiation
counterparts of VCUG and DMSA [31, 32, 34, 36–42]. Contrast-
enhanced voiding urosonography is a highly sensitive, alternative
imaging modality for the evaluation of VUR in children and in
many centers it has replaced the traditionally performed VCUG
[35, 133]. New US techniques aimed at further improvement of
the diagnostic capabilities of ceVUS include real time three- and
four-dimensional ceVUS, which enables the volumetric visualiza-
tion of contrast within a refluxing pelvicalyceal system, poten-
tially improving grading [29], whereas intraoperative ceVUS can
be used during endoscopic treatment of vesicoureteral reflux in
children for direct evaluation of the operative outcome [33].
Technique
Following bladder catheterization, UCA is administered intravesi-
cally and real time US imaging of the kidneys and retrovesical
space is performed during subsequent cycles of bladder filling
and voiding with the child in supine and/or prone positions. Re-
garding UCA administration into the bladder during ceVUS per-
formance, two techniques have been developed, the one most
commonly used entails direct UCA injection into a partially filled
bladder [134]. The other method entails the administration of
UCA into a saline bag and subsequent drip infusion of the solu-
tion via the catheter into the bladder [42]. The presence of echo-
genic microbubbles within the ureter, renal pelvis and calyces is
indicative of VUR, graded in a similar manner to VCUG. At the end
of the examination morphological and functional study of the ur-
ethra is performed during a dedicated voiding cycle, using trans-
perineal or transabdominal scanning approach [39].
Level of Evidence
Numerous studies have demonstrated the high sensitivity of ce-
VUS for the detection and grading of VUR. From the time when
second generations UCA became commercially available, 14 ori-
ginal studies have been conducted with the intravesical use of
SonoVue™/Lumason™ for the diagnosis of VUR including 2087
children [29, 31–42, 133]. The majority of these studies are com-
parative studies entailing the consecutive performance of ceVUS
and VCUG; in only two studies was ceVUS the only examination
performed. The studies that compared csVUS and VCUG have
demonstrated the superiority of ceVUS over VCUG in detecting
higher grade VUR, hence of greater clinical significance. The lar-
gest study recruited 1010 children and was primarily devoted to
the safety evaluation of the intravesical administration of Sono-
Vue™/Lumason™ [35]. In addition, it is possible to image the ur-
ethra and accurately depict urethral abnormalities with a good
diagnostic correlation as with VCUG [133]. A European survey
has shown that ceVUS is being widely performed and up to
2012, a total of 4131 ceVUS examinations have been safely per-
formed in 29 European centers [28].
Position Comment
Contrast-enhanced voiding urosonography has proven to be a
safe and reliable imaging technique for detecting VUR and ure-
thral abnormalities in children of both genders.
Future Perspectives
▼
Contrast-enhanced ultrasound has a number of distinct and well
known advantages over CT and MR imaging, particularly in chil-
dren, highly important for the future perspectives of CEUS [45,
135]. The uncertainty surrounding the long-term effects of gado-
linium deposition in children is a concern will drive the use of
CEUS in children [136]. In addition to licensed indications with a
focus on the liver and Doppler enhancement, CEUS is safe and ef-
fective for examination of almost all organs in adults, as indicated
by the EFSUMB guidelines [6, 7]. “Off-label” use (and its funding)
is the challenge in paediatric practice becausemany drugs are not
tested by randomized trials in children, which also means that
they are not specifically licensed for use in children. The recent
licensing of SonoVue™/Lumason™ for use in paediatric liver US
in the United States is a welcome first step towards the accep-
tance of this technique in the imaging of children.
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